Royalty Pharma (RPRX) reported Q4 net income Tuesday of $208 million, down from $494 million a year earlier.

Comparable analyst estimates were not available.

Total income and other revenues ended Dec. 31 were $594 million, down from $596 million a year earlier.

Analysts surveyed by FactSet expected $687 million.

As of Dec. 31, the company said it had $929 million in cash and cash equivalents.

Shares of the UK biopharmaceutical company were up more than 2% in Tuesday's premarket activity.

Price: 32.45, Change: +0.73, Percent Change: +2.30